Skip to content

Study · Randomized controlled trial · 2023

4 results

Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial.

Rahman F, McLaughlin T, Mesquita P, Morin J, Potvin D, De Chantal M, Aberg JA

Journal of clinical and translational science7 Dec 2022Cited by 1 (Europe PMC)

PMID36845310 (opens in a new tab)PMCIDPMC9947601 (opens in a new tab)DOI10.1017/cts.2022.515 (opens in a new tab)PepBankPUB-36845310
Download PDFPubMedAsk about this study
Jump to 4 results

Summary

Tesamorelin, a synthetic growth hormone-releasing hormone, is indicated for the reduction of visceral adipose tissue (VAT) in people with HIV. Here, we performed a post hoc analysis of participants receiving tesamorelin for 26 weeks in a phase III clinical trial. Efficacy data were compared between individuals with and without dorsocervical fat, stratified by tesamorelin response. Among tesamorelin responders, VAT and waist circumference (WC) decreased in both dorsocervical fat groups and did not statistically differ (VAT P = 0.657, WC P = 0.093). These data demonstrate that tesamorelin is equally effective and should be considered in the treatment of excess VAT regardless of the presence of dorsocervical fat.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In tesamorelin responders with HIV, visceral adipose tissue decreased both with and without dorsocervical fat.

    In plain wordsIn people with HIV who responded to tesamorelin, visceral fat decreased whether or not they had dorsocervical fat.

    Peptide
    Tesamorelin
    Outcome
    DecreaseVisceral adipose tissue change in responders
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Among tesamorelin responders, VAT and waist circumference (WC) decreased in both dorsocervical fat groups and did not statistically differ (VAT P = 0.657, WC P = 0.093).
    2 context sentences
    Summary · context
    Here, we performed a post hoc analysis of participants receiving tesamorelin for 26 weeks in a phase III clinical trial.
    Summary · context
    Efficacy data were compared between individuals with and without dorsocervical fat, stratified by tesamorelin response.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In tesamorelin responders with HIV, waist circumference decreased both with and without dorsocervical fat.

    In plain wordsIn people with HIV who responded to tesamorelin, waist size decreased whether or not they had dorsocervical fat.

    Peptide
    Tesamorelin
    Outcome
    DecreaseWaist circumference change in responders
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Among tesamorelin responders, VAT and waist circumference (WC) decreased in both dorsocervical fat groups and did not statistically differ (VAT P = 0.657, WC P = 0.093).
    2 context sentences
    Summary · context
    Here, we performed a post hoc analysis of participants receiving tesamorelin for 26 weeks in a phase III clinical trial.
    Summary · context
    Efficacy data were compared between individuals with and without dorsocervical fat, stratified by tesamorelin response.
  3. 03HumanObservational studyEfficacy outcome

    Among tesamorelin responders, the VAT decrease did not differ statistically between those with and without dorsocervical fat.

    In plain wordsAmong people who responded to tesamorelin, the visceral fat decrease was not clearly different with or without dorsocervical fat.

    Peptide
    Tesamorelin
    Outcome
    No significant changeVAT response by dorsocervical fat status
    Study

    n: not reported in source

    Comparator
    Participants without dorsocervical fat
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Measurements

    P value for VAT difference between groups
    0.657 NA
    with vs without dorsocervical fat

    Source sentences

    Summary
    Among tesamorelin responders, VAT and waist circumference (WC) decreased in both dorsocervical fat groups and did not statistically differ (VAT P = 0.657, WC P = 0.093).
    2 context sentences
    Summary · context
    Here, we performed a post hoc analysis of participants receiving tesamorelin for 26 weeks in a phase III clinical trial.
    Summary · context
    Efficacy data were compared between individuals with and without dorsocervical fat, stratified by tesamorelin response.
  4. 04HumanObservational studyEfficacy outcome

    Among tesamorelin responders, the waist circumference decrease did not differ statistically between those with and without dorsocervical fat.

    In plain wordsAmong people who responded to tesamorelin, the waist size decrease was not clearly different with or without dorsocervical fat.

    Peptide
    Tesamorelin
    Outcome
    No significant changeWaist circumference response by dorsocervical fat status
    Study

    n: not reported in source

    Comparator
    Participants without dorsocervical fat
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Measurements

    P value for WC difference between groups
    0.093 NA
    with vs without dorsocervical fat

    Source sentences

    Summary
    Among tesamorelin responders, VAT and waist circumference (WC) decreased in both dorsocervical fat groups and did not statistically differ (VAT P = 0.657, WC P = 0.093).
    2 context sentences
    Summary · context
    Here, we performed a post hoc analysis of participants receiving tesamorelin for 26 weeks in a phase III clinical trial.
    Summary · context
    Efficacy data were compared between individuals with and without dorsocervical fat, stratified by tesamorelin response.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.